Introduction: Neuromuscular blocking drugs help with endotracheal intubation and surgical relaxation by interrupting nerve impulse transmission at the neuromuscular junction. The triad of narcosis, analgesia, and muscle relaxation has been reinterpreted as anaesthesia. Atracurium is an intermediate acting NDMR which is often used in renal and hepatic failure. Cisatracurium is 3 to 4 times more potent than Atracurium and may not produce the same excellent intubating results as equipotent dosages of Atracurium. Materials And Methods: This prospective, randomized, double blinded study was conducted between December 2019 to June 2021 on 60 patients of ASA PS I and II undergoing elective surgery under General anaesthesia. Patients fulfilling the inclusion criteria were randomly were randomly divided into 2 groups of 30 in each group; Group A – Atracurium 0.5 mg/kg and Group C – Cisatracurium 0.15 mg/kg .The drug was administered by an anaesthesiologist unrelated to the study by closed envelope method. The mean onset and duration of action of neuromuscular blockade was calculated for both the groups. Results: The Statistical analysis showed that the mean onset of blockade was found to be significantly longer in Atracurium group (3.32± 0.35 min) compared to Cisatracurium group (3.03±0.36 min).Duration of action was significantly longer in group C (40.60 ± 4.70 minutes) when compared to group A (32.50 ±4.17 minutes). Conclusion: Based on the present clinical comparative study, 0.15mg/kg (3× ED95) of Cisatracurium provides more effective neuromuscular blocking than 0.5mg/kg (2× ED95) of Atracurium in terms of time of onset and duration of neuromuscular blockade.

Introduction: Neuromuscular blocking drugs help with endotracheal intubation and surgical relaxation by interrupting nerve impulse transmission at the neuromuscular junction. The triad of narcosis, analgesia, and muscle relaxation has been reinterpreted as anaesthesia. Atracurium is an intermediate acting NDMR which is often used in renal and hepatic failure. Cisatracurium is 3 to 4 times more potent than Atracurium and may not produce the same excellent intubating results as equipotent dosages of Atracurium. Materials And Methods: This prospective, randomized, double blinded study was conducted between December 2019 to June 2021 on 60 patients of ASA PS I and II undergoing elective surgery under General anaesthesia. Patients fulfilling the inclusion criteria were randomly were randomly divided into 2 groups of 30 in each group; Group A – Atracurium 0.5 mg/kg and Group C – Cisatracurium 0.15 mg/kg .The drug was administered by an anaesthesiologist unrelated to the study by closed envelope method. The mean onset and duration of action of neuromuscular blockade was calculated for both the groups. Results: The Statistical analysis showed that the mean onset of blockade was found to be significantly longer in Atracurium group (3.32± 0.35 min) compared to Cisatracurium group (3.03±0.36 min).Duration of action was significantly longer in group C (40.60 ± 4.70 minutes) when compared to group A (32.50 ±4.17 minutes). Conclusion: Based on the present clinical comparative study, 0.15mg/kg (3× ED95) of Cisatracurium provides more effective neuromuscular blocking than 0.5mg/kg (2× ED95) of Atracurium in terms of time of onset and duration of neuromuscular blockade.